Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.

abstract：INTRODUCTION:Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence. We performed a systematic review and meta-analysis to describe the efficacy of strategies to improve adherence to stroke secondary prevention. MET...

journal_title：Cardiovascular therapeutics

authors： Al AlShaikh S,Quinn T,Dunn W,Walters M,Dawson J

更新日期：2016-04-01 00:00:00

abstract：AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...

journal_title：Cardiovascular therapeutics

authors： Xu K,Han Y,Xu B,Yang Y,Wang G,Li H,Sun Y,Tao L,Wang H,Yuan Z,Liu H,Liu J,Jia Y,Ma G,Fu G,Li X,Li S,Wang S,Pu K,CREDIT 2 Investigators.

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:The antianginal agent ranolazine (R) has shown some promise as an antiarrhythmic agent but its mechanism of action is not known. Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr. PURPOSE:The present study was ca...

journal_title：Cardiovascular therapeutics

authors： Kloner RA,Dow JS,Bhandari A

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an ...

journal_title：Cardiovascular therapeutics

authors： Cobas M,Paparcuri G,De La Pena M,Cudemus G,Barquist E,Varon A

更新日期：2011-08-01 00:00:00

abstract：AIMS:We investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites. METHODS:Sixty healthy subjects (39 male, 21 female; age 20-45 years) were randomized to receive a single subcu...

journal_title：Cardiovascular therapeutics

authors： Lunven C,Paehler T,Poitiers F,Brunet A,Rey J,Hanotin C,Sasiela WJ

更新日期：2014-12-01 00:00:00

abstract：:Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal...

journal_title：Cardiovascular therapeutics

authors： Lim TK,Choy AJ,Khan F,Belch JJ,Struthers AD,Lang CC

更新日期：2009-04-01 00:00:00

abstract：OBJECTIVES:Endothelial progenitor cells (EPCs) have been shown to participate in the process of vascular repair, thus playing a protective role against cardiovascular disease (CVD). It is known that atherosclerotic risk factors could affect EPC number and function. Advanced glycation end products (AGEs) contribute to t...

journal_title：Cardiovascular therapeutics

authors： Ueda S,Yamagishi S,Matsui T,Noda Y,Ueda S,Jinnouchi Y,Sasaki K,Takeuchi M,Imaizumi T

更新日期：2012-08-01 00:00:00

abstract：Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...

journal_title：Cardiovascular therapeutics

authors： Chen Z,Liu Z,Li N,Liu R,Wang M,Wang D,Li C,Li K,Luo F,He Y

更新日期：2021-01-13 00:00:00

abstract：AIM:Cardiac hypertrophy and myocardial fibrosis significantly contribute to the pathogenesis of diabetic cardiomyopathy (DCM). Altered expression of several genes and their regulation by microRNAs has been reported in hypertrophied failing hearts. This study aims to examine the role of Cdc42, Pak1, and miR-30c in the p...

journal_title：Cardiovascular therapeutics

authors： Raut SK,Kumar A,Singh GB,Nahar U,Sharma V,Mittal A,Sharma R,Khullar M

更新日期：2015-06-01 00:00:00

abstract：BACKGROUND:Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting. METHODS:We ...

journal_title：Cardiovascular therapeutics

authors： Krum H,van Veldhuisen DJ,Funck-Brentano C,Vanoli E,Silke B,Erdmann E,Follath F,Ponikowski P,Goulder M,Meyer W,Lechat P,Willenheimer R,behalf of the CIBIS III Investigators.

更新日期：2011-04-01 00:00:00

abstract：:This study aimed to investigate the correlation between complement C1q tumor necrosis factor-related protein 1 (CTRP1) and subclinical target organ damage (STOD) in essential hypertension (EH). 720 patients were enrolled in this study, including 360 healthy subjects and 360 patients with EH. The EH group included 183 ...

journal_title：Cardiovascular therapeutics

authors： Su Z,Tian S,Liang W

更新日期：2019-06-02 00:00:00

abstract：AIMS:cardiopulmonary bypass and cardiac surgery are associated with a significant systemic inflammatory response that has been suggested playing a causative role in the development of perioperative atrial fibrillation (POAF). The goal of this meta-analysis was to determine the efficacy of glucocorticoid prophylaxis in ...

journal_title：Cardiovascular therapeutics

authors： Liu C,Wang J,Yiu D,Liu K

更新日期：2014-06-01 00:00:00

abstract：Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

journal_title：Cardiovascular therapeutics

authors： Sunjaya AF,Sunjaya AP

更新日期：2019-04-01 00:00:00

abstract：INTRODUCTION:Rap1, a member of Ras superfamily of small GTP-binding proteins, is involved in cardiovascular biology in numerous ways. It is an evolutionary conserved regulator of adhesion, polarity, differentiation and growth. AIMS:Our aim was to analyze Rap1-activated rat bone marrow mesenchymal stem cells (MSCs) for...

journal_title：Cardiovascular therapeutics

authors： Khan I,Ali A,Akhter MA,Naeem N,Chotani MA,Iqbal H,Kabir N,Atiq M,Salim A

更新日期：2017-04-01 00:00:00

abstract：AIM:To assess the effect of Cytochrome P450 2C9 (CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. METHODS:A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were identified and compared a...

journal_title：Cardiovascular therapeutics

authors： Zhang J,Tian L,Huang J,Huang S,Chai T,Shen J

更新日期：2017-02-01 00:00:00

abstract：INTRODUCTION:The effectiveness of statin pretreatment in reducing the incidence of contrast-induced nephropathy (CIN) has been examined in some observational and randomized studies, yielding controversial results. AIM:This study sought to evaluate the role of atorvastatin in prevention of CIN in diabetic patients with...

journal_title：Cardiovascular therapeutics

authors： Shehata M,Hamza M

更新日期：2015-04-01 00:00:00

abstract：:Cilnidipine is a unique Ca(2+) channel blocker with an inhibitory action on the sympathetic N-type Ca(2+) channels, which is used for patients with hypertension in Japan. Cilnidipine has been clarified to exert antisympathetic actions in various examinations from cell to human levels, in contrast to classical Ca(2+) c...

journal_title：Cardiovascular therapeutics

authors： Takahara A

更新日期：2009-07-01 00:00:00

abstract：:There is increasing evidence to suggest that chronic heart failure (CHF) is an insulin resistant (IR) state and that the degree of IR correlates with the severity and mortality of CHF. The pathophysiology of IR in CHF has yet to be fully defined. Additionally, it remains to be determined if IR is merely a marker refle...

journal_title：Cardiovascular therapeutics

authors： Wong AK,AlZadjali MA,Choy AM,Lang CC

更新日期：2008-10-01 00:00:00

abstract：INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...

journal_title：Cardiovascular therapeutics

authors： Farkowski MM,Maciag A,Zurawska M,Kowalik I,Szwed H,Pytkowski M

更新日期：2018-12-01 00:00:00

abstract：:Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination...

journal_title：Cardiovascular therapeutics

authors： Cohen M,Iyer D

更新日期：2014-10-01 00:00:00

abstract：:Atrial fibrillation (AF) has been defined as the new cardiovascular "epidemic". Its prevalence is rising in developed countries, and the associated social and economic costs are high. In the last few years, there has been an increasing interest in understanding the mechanisms of AF and its management. New pharmacother...

journal_title：Cardiovascular therapeutics

authors： Romero I,Nedios S,Kriatselis C

更新日期：2014-10-01 00:00:00

abstract：:The genetic causes of cholesterol metabolism disorders usually lead to premature atherosclerosis. The most well recognized genetically caused hypercholesterolemia is familial hypercholesterolemia. Although the disease is well known, as the discovery of low-density lipoprotein receptor, the classical treatment with lip...

journal_title：Cardiovascular therapeutics

authors： Kolovou G,Vasiliadis I,Gontoras N,Kolovou V,Hatzigeorgiou G

更新日期：2015-04-01 00:00:00

abstract：:Sex-specific differences have been definitively demonstrated in cardiovascular (CV) diseases. These differences can also impact on the effects of CV therapies. Female sex is recognized as an independent predictor of thromboembolic risk, particularly in older patients. Most of strokes are due to atrial fibrillation (AF...

journal_title：Cardiovascular therapeutics

authors： Gallù M,Marrone G,Legramante JM,De Lorenzo A,Di Daniele N,Noce A

更新日期：2020-06-18 00:00:00

abstract：AIM:This study was designed to explore the mechanism of physiological ischemic training (PIT) on remote limbs, with a special focus on the potential role of endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), and nitric oxide (NO) in local ischemic myocardium. METHOD:Myocardial ischemia (MI...

journal_title：Cardiovascular therapeutics

authors： Zheng Y,Xiao M,Li L,Li J,Reinhardt JD,Lu X

更新日期：2017-06-01 00:00:00

abstract：:Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others ha...

journal_title：Cardiovascular therapeutics

authors： Whayne TF Jr

更新日期：2010-04-01 00:00:00

abstract：:Potassium (K(+) ) channels are important in cardiovascular disease both as drug targets and as a cause of underlying pathology. Voltage-dependent K(+) (K(V) ) channels are inhibited by the class III antiarrhythmic agents. Certain vasodilators work by opening K(+) channels in vascular smooth muscle cells (VSMCs), and...

journal_title：Cardiovascular therapeutics

authors： Goonetilleke L,Quayle J

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore,...

journal_title：Cardiovascular therapeutics

authors： Kawashiri MA,Yamagishi M,Sakamoto T,Takayama T,Hiro T,Daida H,Hirayama A,Saito S,Yamaguchi T,Matsuzaki M,COSMOS Investigators.

更新日期：2013-12-01 00:00:00

abstract：:Clopidogrel is an inhibitor of the ADP receptor P2Y12 and platelet aggregation. It is widely used for the management of atherothrombotic disease in patients who have experienced severe vascular events such as stroke or myocardial infarction or with peripheral artery disease. However, some patients show "resistance" to...

journal_title：Cardiovascular therapeutics

authors： Uchiyama S

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Levosimendan is a noncatecholamine inotrope that does not increase oxygen consumption, utilized for the treatment for acute heart failure with left ventricular (LV) systolic dysfunction. Its use in takotsubo cardiomyopathy (TTC), a disease that contraindicates the use of catecholamine inotropes, is not well ...

journal_title：Cardiovascular therapeutics

authors： Santoro F,Ieva R,Ferraretti A,Ienco V,Carpagnano G,Lodispoto M,Di Biase L,Di Biase M,Brunetti ND

更新日期：2013-12-01 00:00:00

abstract：AIM:Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent. METHODS:A complete community-based heart failure population was studied. ...

journal_title：Cardiovascular therapeutics

authors： Jonsson A,Norberg H,Bergdahl E,Lindmark K

更新日期：2018-10-01 00:00:00